Feasibility and usability of remote monitoring in Alzheimer's disease

Marijn Muurling, Casper de Boer*, Chris Hinds, Alankar Atreya, Aiden Doherty, Vasilis Alepopoulos, Jelena Curcic, Anna-Katharine Brem, Pauline Conde, Sajini Kuruppu, Xavier Morató, Valentina Saletti, Samantha Galluzzi, Estefania Vilarino Luis, Sandra Cardoso, Tina Stukelj, Milica Gregoric Kramberger, Dora Roik, Ivan Koychev, Ann-Cecilie HopøyEmilia Schwertner, Mara Gkioka, Dag Aarsland, Pieter Jelle Visser, RADAR-AD Consortium

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

INTRODUCTION: Remote monitoring technologies (RMTs) can measure cognitive and functional decline objectively at-home, and offer opportunities to measure passively and continuously, possibly improving sensitivity and reducing participant burden in clinical trials. However, there is skepticism that age and cognitive or functional impairment may render participants unable or unwilling to comply with complex RMT protocols. We therefore assessed the feasibility and usability of a complex RMT protocol in all syndromic stages of Alzheimer's disease and in healthy control participants. METHODS: For 8 weeks, participants (N = 229) used two activity trackers, two interactive apps with either daily or weekly cognitive tasks, and optionally a wearable camera. A subset of participants participated in a 4-week sub-study (N = 45) using fixed at-home sensors, a wearable EEG sleep headband and a driving performance device. Feasibility was assessed by evaluating compliance and drop-out rates. Usability was assessed by problem rates (e.g., understanding instructions, discomfort, forgetting to use the RMT or technical problems) as discussed during bi-weekly semi-structured interviews. RESULTS: Most problems were found for the active apps and EEG sleep headband. Problem rates increased and compliance rates decreased with disease severity, but the study remained feasible. CONCLUSIONS: This study shows that a highly complex RMT protocol is feasible, even in a mild-to-moderate AD population, encouraging other researchers to use RMTs in their study designs. We recommend evaluating the design of individual devices carefully before finalizing study protocols, considering RMTs which allow for real-time compliance monitoring, and engaging the partners of study participants in the research.
Original languageEnglish
JournalDigital health
Volume10
DOIs
Publication statusPublished - 9 Apr 2024

Keywords

  • Alzheimers < disease
  • apps < personalised medicine
  • dementia < disease
  • digital health < general
  • eHealth < general
  • neurology < medicine
  • remote clinical trials < studies
  • remote patient monitoring <personalised medicine
  • wearables < personalised medicine

Cite this